Zafardoost et al., randomized 40 patients with moderate-severe DAI to 1.25 mg oral GLI every 12 h (this dose was increased to 2.5 mg if no hypoglycemia was noted at the lower dose) vs. control (no placebo) [133]. The gene discussed is GLI1; the disease is Hypoglycemia.